February 2, 2012
Alizé Pharma licenses its ASPAREC® therapy for Treatment of Acute Lymphoblastic Leukemia (ALL) to EUSA Pharma


Read more...

ICE / ECE 2012
Florence - Italy,
May 5-9, 2012

2012 BIO International Convention
Boston - MA,
June 18-21, 2012

ENDO 2012
Houston, TX
June 23-26, 2012

Read more...

Alizé Pharma is a group of privately held biopharmaceutical companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and cancer.

The first entity of the Group, Alizé Pharma SAS, is focused on the AZP-01 program, a peptide derived from unacylated ghrelin, currently at the preclinical stage of development for the treatment of Type II diabetes and other metabolic and cardiovascular indications.

The second company, Alizé Pharma II SAS, is dedicated to the development of ASPAREC® (AZP-02), a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, and currently in Phase I clinical development.

 
Alizé Pharma © 2007 Legal disclaim